Posted on November 23, 2016 by Chris Hughes
The Genotoxicity specialist Gentronix is pleased to announce that Dr. Matt Tate has joined the Gentronix Ltd Board as Technical Director, effective 1st November 2016. Dr Tate joined the company in 2006 and has developed an in-depth knowledge of the field with several publications to his name and an ability to provide quality, customised advice to customers.
John Nicholson, Gentronix Chairman, commented that “Matt Tate has developed a terrific awareness of what is current in the genotoxicity field and has become increasingly well regarded in his field and we are confident that he will make a significant contribution to the Gentronix Board.”
At the same time, Professor Richard Walmsley, founder of the company, will become President of Gentronix, and though he will stand down from the Board, he will consult for the company on scientific initiatives and continue to represent Gentronix on several international genotoxicity bodies. Richard has contributed significantly to the world of genotoxicity over the last decade or more, and will continue also with new research into epigenetics at the University of Manchester. The company looks forward to continuing to work with him in his new capacity.